SLE Classification Criteria
Oral or nasal ulcers (a) and arthritis of two or more joints (b) are included in SLE classification criteria, while thrombocytosis (c) and pulmonary infiltrates with eosinophilia (e) are NOT part of SLE criteria; renal damage (d) IS included.
Breakdown of Each Option
a) Oral or Nasal Ulcers - INCLUDED ✓
Oral ulcers are explicitly part of all major SLE classification systems 1. The 2019 EULAR/ACR criteria include oral ulcers as a weighted criterion in the mucocutaneous domain 2. These ulcers are typically painless and occur on the palate, buccal mucosa, or tongue. Nasal ulcers are also recognized as part of the mucocutaneous manifestations 3.
b) Arthritis of Two or More Joints - INCLUDED ✓
Arthritis involving multiple joints is a core criterion in SLE classification 4, 5. The 2019 EULAR/ACR criteria specifically score joint involvement, with different points assigned based on the number and type of joints affected (small vs. large joints) 2. The criteria recognize that SLE arthritis typically involves:
- Small joints (metacarpophalangeal, proximal interphalangeal joints, wrists)
- Large joints (shoulders, elbows, knees, ankles)
- Bilateral, symmetric pattern common
c) Thrombocytosis - NOT INCLUDED ✗
This is the opposite of what appears in SLE criteria. SLE classification criteria include thrombocytopenia (low platelets <100,000/μL), not thrombocytosis (elevated platelets) 5, 6. Thrombocytopenia is part of the hematologic domain in all major classification systems. Thrombocytosis would actually argue against SLE as the primary diagnosis.
d) Renal Damage - INCLUDED ✓
Renal involvement is a major criterion in all SLE classification systems 1, 7, 8. The 2019 EULAR/ACR criteria assign the highest weight (10 points) to Class III or IV lupus nephritis, which alone can classify a patient as having SLE 2. Renal manifestations include:
- Proteinuria (>0.5 g/24 hours)
- Hematuria
- Cellular casts
- Biopsy-proven lupus nephritis 6
The EULAR 2023 update emphasizes that lupus nephritis requires aggressive treatment with mycophenolate or cyclophosphamide plus glucocorticoids, with consideration of add-on belimumab or calcineurin inhibitors 8.
e) Pulmonary Infiltrates with Eosinophilia - NOT INCLUDED ✗
This combination is NOT part of SLE classification criteria. While SLE can cause various pulmonary manifestations (pleuritis, pleural effusions, interstitial lung disease), pulmonary infiltrates with eosinophilia are characteristic of other conditions 9:
- Eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss)
- Parasitic infections (Löffler's syndrome)
- Drug reactions
The evidence clearly shows that eosinophilia with pulmonary infiltrates is a defining feature of EGPA, not SLE 9. In fact, if a patient presents with these findings, alternative diagnoses should be strongly considered.
Critical Distinction
The 2019 EULAR/ACR criteria require positive ANA (≥1:80 titer) as an entry criterion before applying other classification criteria 1, 2. This is a fundamental change from previous systems and must be satisfied first. After meeting this entry criterion, patients need a cumulative weighted score of ≥10 points from clinical and immunologic domains to be classified as SLE.
Common Pitfall
Do not confuse SLE criteria with other autoimmune conditions. Eosinophilia and thrombocytosis are red flags that should prompt consideration of alternative diagnoses rather than supporting SLE classification.